Replies to post #236168 on Biotech Values

[DFRAI]

BCRX vs ALXN

Its not looking at Alxn 5 billion revenue that garnered 39 billion offer,
that i am suggesting

BCrx is undervalued and has the potential to be a growth stock for a few years with Factor D driving value. Factor D is set to enter clinic in multiple indications next year all financed with cash on hand, line of credit and from revenue generated by Orladeyo which has 500+ million potential.

GLTL